♎️ 🔮

Bay Area, Cali Grown 🍁

[♎️ 🔮 @SweetXHart11]

@MarioNawfal 🥺 I’m allergic to cats but I would take this little baby home 🥹

[♎️ 🔮 @SweetXHart11]

@trollallaaa @DaniMayakovski Ouchie

[♎️ 🔮 @SweetXHart11]

@Hoopss First try baby

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN @Ocugen @drsmusunuri 👇 ♥️ ❤️ 😍

[Mr.OcugenInvestor @kickstarterx10]

$OCGN Ocugen Price Target Announced at $10.00/Share by Oppenheimer

https://t.co/da2GEB1XG2

[♎️ 🔮 @SweetXHart11]

@HumanityChad Not having me bawling first thing in the morning 😭😭😭😭❤️

[♎️ 🔮 @SweetXHart11]

After all this time are we finally about to break $2.00 ?! $OCGN

[♎️ 🔮 @SweetXHart11]

@awkwardgoogle 😭

[♎️ 🔮 @SweetXHart11]

@WallStreetApes This looks like something out of black mirror

[♎️ 🔮 @SweetXHart11]

$OCGN makes me so proud 🥺

[Supplements Manufacturer @MoreFlax]

#OCUGEN $OCGN..... $15 price target sounds good, but very conservative imo.

[♎️ 🔮 @SweetXHart11]

@okimstillhungry Lmao what 😂🤮

[SGimvesting @sgunderbarth]

$OCGN if you think holding in the red is difficult, try holding in the green. Patience for patients.

[♎️ 🔮 @SweetXHart11]

@vemby_marfico Terrifying

[♎️ 🔮 @SweetXHart11]

@xKnowledgeBANK I put my child in ISR around 6.5 months. Living in Florida w/ a high drowning rate, as well as owning a pool … I had to get her lessons asap.

[Guy @GuyCreal]

$ocgn I truly believe this stock will be financially life changing for many people not to mention life changing medically. Blindness gene therapy that clearly works. Co signed deal with S. Korean co & many countries to follow soon including the US. $20+ stock $tsla $btc $spy $qqq

[Mr.OcugenInvestor @kickstarterx10]

$OCGN Ocugen’s Strategic Advancements and Promising Prospects Justify Buy Rating

https://t.co/DHgWY2ofLm

[Life Science Report @lifesciencerpt]

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea $OCGN https://t.co/IgUWwBnvzX

[TheUrbanFarmer @NattaCop]

$ocgn Here’s some added context: the standard of care for GA (Apellis’ Syfovre & Iveric’s Izervay) showed 14–18% slowing of lesion growth after monthly injections for 12 months vs sham.

Ocu410 just showed a 80% relative reduction at 6 months, from a single administration vs the endless injections required with Syfovre/Izervay.

For perspective, Izervay was Iveric’s only late stage asset when Astellas acquired them for $5.9B.

Do what you will with that info. As for me? I’m gonna get rich 🤑 💸 🏦 🍻